U.S. markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8900+0.1600 (+9.25%)
At close: 04:00PM EDT
1.8800 -0.01 (-0.53%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close1.7300
Bid1.8700 x 38500
Ask1.8800 x 29200
Day's Range1.7200 - 1.8900
52 Week Range1.3800 - 9.9600
Avg. Volume6,369,822
Market Cap432.887M
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-1.5420
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for INO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inovio Pharmaceuticals, Inc.
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • PR Newswire

    INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that in connection with the hiring of Dr. Michael John Sumner as Chief Medical Officer, announced on June 27, 2022, the Compensation Committee of INOVIO's Board of Directors approved equity grants to Dr. Sumner as inducement awards under INOVIO's 2022 Inducement Plan (the "In

  • American City Business Journals

    Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options

    This week's Lab Notes has items on a Chester County company's ongoing pursuit of approval for its lead drug candidate, a Bucks County company exploring its options after generating positive study results for an experimental angina drug, two local life sciences companies naming new chief medical officers, and more.

  • Motley Fool

    Why Inovio Pharmaceuticals Stock Topped the Market on Monday

    Inovio Pharmaceuticals (NASDAQ: INO) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. Previous to that, he worked in various positions at U.K. pharmaceutical company Shire in a stint that lasted roughly six years, and also held positions at Novartis and Novo Nordisk.